Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

NCT04129502 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT04129502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04129502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 10, 2020
Completion date
October 31, 2026
Enrollment
354 (actual)
Sites
134

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic non-small cell lung cancer (nsclc)